A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas

Radiotherapy and Oncology

Volumn 79, Issue 1, 2006, Pages 34-38

  Medina, José Antonio ^a   Rueda, Antonio ^a   de Pasos, Antonio Sacchetti ^b   Contreras, Jorge ^a   Cobo, Manuel ^a   Moreno, Paloma ^b   Benavides, Manuel ^a   Villanueva, Asunción ^a   Alba, Emilio ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b CROASA Centro Radio Oncológico Andaluz   (Spain)

Author keywords

Accelerated; Head and neck; Hyperfractionated; Radiotherapy; Squamous cell

Indexed keywords

ANALGESIC AGENT; CISPLATIN; ERYTHROPOIETIN; FENTANYL; OPIATE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DERMATITIS; DRUG EFFICACY; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; OROPHARYNX CANCER; OVERALL SURVIVAL; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33646205451     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.03.010     Document Type: Article

References (37)

1. Bernier J., and Bentzen S.M. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 39 (2003) 560-571
2. Beckmann G.K., Hoppe F., Pfreundner L., and Flentje M.P. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27 (2005) 36-43
3. Pinto L.H., Canary P.C., Araujo C.M., Bacelar S.C., and Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21 (1991) 557-562
4. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25 (1992) 231-241
5. Fu K.K., Pajak T.F., Trotti A., et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
6. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
7. Crissman J.D., Pajak T.F., Zarbo R.J., Marcial V.A., and Al-Sarraf M. Improved response and survival to combined cisplatin and radiation in non-keratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors. Cancer 59 (1987) 1391-1397
8. Marcial V.A., Pajak T.F., Mohiuddin M., et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the radiation therapy oncology group study 81-17. Cancer 66 (1990) 1861-1868
9. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
10. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
11. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
12. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
13. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23 (2005) 1125-1135
14. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
15. Browman G.P., Hodson D.I., Mackenzie R.J., Bestic N., and Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23 (2001) 579-589
16. Bourhis J.S.N., Overgaard J., Ang K.K., et al. Conventional vs modified fractionated radiotherapy. meta-analysis of radiotherapy in head & necksquamous cell carcinoma: a meta-analysis based on individual patient data. Int J Radiat Oncol Biol Phys (2004) S190-S191
17. Van den Bogaert W., van der Schueren E., Horiot J.C., et al. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother Oncol 35 (1995) 91-99
18. Withers H.R., Taylor J.M., and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
19. DeWitt L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13 (1987) 403-426
20. Allal A.S., Taussky D., Mach N., Becker M., Bieri S., and Dulguerov P. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Int J Radiat Oncol Biol Phys 58 (2004) 1431-1436
21. Ang K.K., Harris J., Garden A.S., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
22. Forastiere A.A. Cisplatin and radiotherapy in the management of locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 27 (1993) 465-470
23. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
24. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
25. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18 (2000) 1458-1464
26. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
27. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
28. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
29. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
30. Harrison L.B., Raben A., Pfister D.G., et al. A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Head Neck 20 (1998) 497-503
31. Widder J., Dobrowsky W., Schmid R., Pokrajac B., Selzer E., and Potter R. Hyperfractionated accelerated radiochemotherapy (HFA-RCT) with mitomycin C for advanced head and neck cancer. Radiother Oncol 73 (2004) 173-177
32. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
33. Kumar S., Pandey M., Lal P., Rastogi N., Maria Das K.J., and Dimri K. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial. Radiother Oncol 75 (2005) 186-192
34. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44 (1997) 111-121
35. Allal A.S., de Pree C., Dulguerov P., Bieri S., Maire D., and Kurtz J.M. Avoidance of treatment interruption: an unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas?. Int J Radiat Oncol Biol Phys 45 (1999) 41-45
36. Teh B.S., Monga U., Thornby J., Gressot L., Parke R.B., and Donovan D.T. Concurrent chemotherapy and 'concomitant boost' radiotherapy for unresectable head and neck cancer. Am J Otolaryngol 21 (2000) 306-311
37. Kessler P.A., Bloch-Birkholz A., Leher A., Neukam F.W., and Wiltfang J. Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study. Radiother Oncol 70 (2004) 275-282